Firefly Bio develops Degrader Antibody Conjugates (DACs) by integrating selective protein degraders with the capabilities of traditional ADCs. Their proprietary platform enables the highly specific delivery of these novel degraders directly to target tissues. This technology allows for the scalable access and utilization of new classes of ADC payloads.
Funding
$94M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional antibody-drug conjugates (ADCs) face limitations in payload delivery and efficacy in targeted cancer therapy. Existing methods may not achieve sufficient drug concentrations within tumor cells, potentially leading to suboptimal therapeutic outcomes.
Solution
Firefly Bio develops Degrader Antibody Conjugates (DACs), a novel class of therapeutics that combines the specificity of ADCs with the mechanism of selective protein degradation. This platform enables precise delivery of protein degraders to target tumor tissues, inducing degradation of specific proteins within cancer cells. By leveraging this approach, Firefly aims to enhance treatment efficacy and improve patient outcomes in cancer therapy.
Target Audience
The primary target audience includes cancer patients and healthcare providers seeking more effective and targeted cancer therapies.
Features
- Proprietary platform for generating Degrader Antibody Conjugates (DACs)
- Highly specific delivery of protein degraders to target tissue
- Induces degradation of specific proteins within cancer cells
- Aims to enhance treatment efficacy compared to traditional ADCs